New expectations in the treatment of terminal kidney cancer

A new treatment for kidney cancer patients may have been a discovery made by researchers at the Dana-Farber Cancer Institute in conjunction with Harvard Medical School.

According to the New England Journal of Medicine , where these two studies were published separately, a combination of medications may be more effective than conventional drugs used to treat cancer.

Despite being positive, the drugs are still in the testing phase and, when completed, still need to be approved by the Federal Agency of the United States Department of Health and Human Services (FDA). This can cause the composition to take longer to become available.

The researchers saw that the combined drugs were able to reduce the tumors of the patient with kidney cancer already in terminal stages, increasing their life span.

In addition, the ability to block the growth of the tumor, preventing some of its molecules from spreading in the body, was greater when compared to other drugs indicated for the treatment of kidney cancer.

Read more: 11 tips to prevent cancer and fight risk factors

What does the first study say?

The first test carried out was with the combination of avelumab + axitinib , against the traditional treatment since 2007, sunitinib .

For this, the scientists brought together a total of 886 patients and divided them into two groups: those who would be treated with the new drugs and those who would take the conventional medicine. And, from there, they started to monitor the effects.

The first group, with 442 patients, took the combined kit (avelumab + axitinib) and then the second group with 444 patients received a conventional treatment drug, sunitinib (a chemotherapy used to treat cancer in advanced stages in the kidney) ).

In the end, when compared, the two types of medication showed different results in the life expectancy that the patients reached.

According to the researchers, the study showed that those who used avelumab + axitinib had, on average, 13.8 months of life. While patients who used the conventional medication had only 7.2 months.

What does the second study say?

For the second test, the researchers also divided 861 participants into 2 groups. The first received the combination of keytruda , whose active ingredient is pembrolizumab, with axitinib.

The patients in the first group, 432 people, received keytruda + axitinib by injection, while the other 429 people in the other group were treated with sunitinib alone.

From then on, the way of comparison was the same, that is, to verify the differences in life expectancy that each drug was able to confer on the patient.

As a result, it was seen that the participants who took the pembrolizumab-axitinib combination had an average of 15.1 months of life, while that of the other group (sunitinib) was 11.1 months.

Thus, the combined treatment was able to decrease the risk of death by 47% and there was a 31% less chance of the disease progressing compared to conventional medicine.

The various researches in this area are considered promising in the treatment of people with kidney cancer, but there is still a need for time, since the tests are still in the testing phase.

The evolution of medicine in the fight against cancer is important in order to give a dignified and painless life to people with the disease.